Navigation Links
Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
Date:6/13/2008

ook for, our operations, research development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in drug discovery and clinical development processes; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development, to expand commercialization activities or consummate acquisitions or to service or repay debt obligations; the accuracy of our estimations of the size of the market, and the potential market, for our products in specific disease areas; sales numbers and future guidance publicly provided by Boston Scientific Corporation regarding sales of their paclitaxel-eluting coronary stent products; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this report to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete preclinical and clin
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
2. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
3. Angiotech appoints Hank McKinnell to its Board of Directors
4. Angiotech to participate in Bank of America Health Care Conference
5. Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO
6. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
7. Angiotechs Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
8. Angiotechs novel 5-FU Central Venous Catheter receives FDA 510(k) clearance
9. Angiotech announces director resignation
10. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
11. Angiotech to participate in Credit Suisse Global Leveraged Finance Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... A new host-based therapy for ... the Keck Graduate Institute and its collaborators. The discovery has the potential to ... online on August 27 by Scientific Reports, an open access research journal from ...
(Date:9/1/2015)... September 1, 2015 Shire plc (LSE: ... Sara Mathew to its Board of Directors as a ... Audit, Compliance & Risk Committee of the Shire Board. Both ... Sara previously served as Chairman, President and Chief Executive ... 2013. During her 12-year tenure at D&B, she helped drive ...
(Date:8/31/2015)... ... August 31, 2015 , ... In recent years, biodegradable ... as low carbon footprints and compostability. These properties can help in limiting the ... the basis of applications, the market for biodegradable plastics can be broadly segmented ...
(Date:8/31/2015)... 31, 2015 Research and Markets ( http://www.researchandmarkets.com/research/k6lcp2/mexico_biomedical ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... The Mexico Biomedical Sensors market is estimated at $0.20 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
Breaking Biology Technology:Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4Shire Appoints Sara Mathew to Board of Directors 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 4Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 5Mexico Biomedical Sensors Market Report 2015-2020 2
... REYKJAVIK, Iceland, April 3, 2008 U.S.,Preventive Medicine(R), ... Genetics, the global leader in gene discovery, today,announced ... add genetic testing to,expand both companies, personalized medicine ... of the letter of intent with deCODE is ...
... Research Results To Be Presented at Experimental Biology ... Wellmune WGP(R), a natural,immune-enhancing ingredient from Biothera, ... for study subjects to miss work or school ... the 2008 Experimental,Biology annual meeting., Don Cox, ...
... ,Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced ... drug candidates at the,American Association for Cancer Research ... at the San Diego Convention Center in San ... histone deacetylase(HDAC),inhibitor, which is now in a multicenter ...
Cached Biology Technology:U.S. Preventive Medicine and deCODE Genetics Sign Letter of Intent to Expand Personalized Medicine Platform 2U.S. Preventive Medicine and deCODE Genetics Sign Letter of Intent to Expand Personalized Medicine Platform 3Wellmune WGP(R) Supplementation Alleviates Duration, Severity and 'Down Time' Due to Cold Symptoms 2Wellmune WGP(R) Supplementation Alleviates Duration, Severity and 'Down Time' Due to Cold Symptoms 3Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting 2Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting 3Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting 4
(Date:8/31/2015)... -- Growing need for data security coupled ... to drive India biometrics market   ... " India Biometrics Market Forecast & Opportunities, 2020 ", biometrics ... grow at a CAGR of over 35% during 2015 - ... extensive use of biometric technology in the government sector. Ongoing ...
(Date:8/24/2015)... , August 24, 2015 The ... ,s largest biometrics manufacturer DERMALOG and its customized solutions ... "2015 African Biometrics Company of the Year Award". DERMALOG is ... Nigeria .   -Cross reference: Picture is ... - On Thursday evening, in ...
(Date:8/19/2015)... Aug. 19, 2015  VOXX International Corporation (Nasdaq: ... entered into a Definitive Agreement to purchase the ... authentication market leader EyeLock through an acquiring entity.  ... a controlling interest in the acquiring entity. The ... of due diligence.  Expanding on its existing supply ...
Breaking Biology News(10 mins):India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... researchers at Oregon State University, the world,s multi-billion dollar foundry ... that produces metal castings used in everything from water pumps ... thousands of years to before Greek and Roman times. It ... continues to evolve. Some modern technologies use various types ...
... Calif -- Nitrogen is a beneficial plant fertilizer in ... ecosystems, such as water pollution, acidification of soils, increased ... a decline of native plant diversity. Over the ... amount of plant-available nitrogen inputs from the atmosphere compared ...
... for Experimental Biology (FASEB) commends Air India for continuing ... company, FASEB expressed its appreciation for Air India,s perseverance ... groups to discontinue shipping laboratory animals. "Animals are crucial ... the world are dependent upon their safe and humane ...
Cached Biology News:Sweet new approach discovered to help produce metal casting parts, reduce toxicity 2Researchers to study impacts of pollutant nitrogen on plant species diversity 2
PlusOne EDTA, disodium salt, 100 g. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Buffers....
...
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
Normal human AB serum, pooled...
Biology Products: